Trial Suggests Optimal Approach to Unresectable CRC Liver Mets
For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the “preferred” systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary tumor, according to a phase III randomized trial. Among these patients, the median progression-free survival (PFS) was 9.0 months in those receiving FOLFOX or FOLFIRI […]